Diabetes Mellitus, Type 1 Clinical Trials in Philadelphia, Pennsylvania

5 studies are recruiting for diabetes mellitus, type 1 in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

   The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.

   Stage

   Phase 3

   Ages

   1 to 35

   Site

   Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania

   Locations

   113 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07222137 on ClinicalTrials.gov

2. A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

   The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.

   Stage

   Phase 3

   Ages

   1 to 35

   Site

   Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania

   Locations

   137 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07222332 on ClinicalTrials.gov

3. A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

   This study will evaluate the safety, tolerability and efficacy of VX-880 infusion and VX-017 infusion in participants with type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   29 in total

   Run by

   Vertex Pharmaceuticals Incorporated

   See if you can join NCT04786262 on ClinicalTrials.gov

4. Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

   This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology ("Control-IQ" which will refer to either Control-IQ or Control-IQ+). T…

   Stage

   Not phased

   Ages

   18 to 65

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   3 in total

   Run by

   Jaeb Center for Health Research

   See if you can join NCT06880835 on ClinicalTrials.gov

5. Closed Loop and Education for Hypoglycemia Awareness Restoration

   The purpose of the CLEAR study is to determine the effect on counterregulatory responses (CRR) of intervening (by attempting to strictly avoid hypoglycemia) to improve awareness of hypoglycemic symptoms among adults with type 1 diabetes (T1D) who have impaired awareness of hypoglycemia (IAH). IAH a…

   Stage

   Not phased

   Ages

   18 to 75

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   8 in total

   Run by

   Milton S. Hershey Medical Center

   See if you can join NCT06325202 on ClinicalTrials.gov